Bavarian Nordic Wins Swiss Approval for Chikungunya Vaccine
COPENHAGEN, Denmark, April 16, 2026 Bavarian Nordic A/S has announced that Swissmedic, the Swiss Agency for Therapeutic Products, has...
Infectious Diseases
Advertisement
Vedanta Biosciences Advances Microbiome Drugs at ESCMID 2026
CAMBRIDGE, Mass., April 9, 2026 Vedanta Biosciences, a late clinical-stage biopharmaceutical company, has announced new scientific presentations showcasing its...
NanoViricides Files Measles Drug for Rare Disease Status
SHELTON, Connecticut, United States, April 7, 2026 NanoViricides, Inc., a clinical-stage biopharmaceutical company, announced that it has filed an...
Shionogi Shows Strong Fetroja Real-World Effectiveness
OSAKA, Japan, April 8, 2026 Shionogi & Co., Ltd. presented new real-world clinical data for Fetroja®/Fetcroja® (cefiderocol) at ESCMID...
NanoViricides Files FDA Orphan Drug Bid for NV-387
Shelton, Connecticut — February 10, 2026: NanoViricides, Inc., a clinical-stage antiviral nanomedicine company, announced the filing of an Orphan...
Advertisements
Early mNGS Testing Cuts Diagnosis Time in CNS Infections
BOSTON, January 22, 2026 — Delve Bio announced new clinical evidence demonstrating that earlier use of metagenomic next-generation sequencing...
Merck’s CAPVAXIVE Shows Strong Immune Response in Children
RAHWAY, N.J. – September 11, 2025 – Merck (NYSE: MRK), known as MSD outside the United States and Canada,...
Advertisement
